474 related articles for article (PubMed ID: 26365713)
21. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
[TBL] [Abstract][Full Text] [Related]
22. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
23. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
24. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH
Am J Manag Care; 2007 Dec; 13 Suppl 10():S270-5. PubMed ID: 18095777
[TBL] [Abstract][Full Text] [Related]
25. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia.
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
Am J Cardiol; 2016 May; 117(9):1444-8. PubMed ID: 26969416
[TBL] [Abstract][Full Text] [Related]
26. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
27. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
28. KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment.
Ruiz-Iruela C; Padró-Miquel A; Pintó-Sala X; Baena-Díez N; Caixàs-Pedragós A; Güell-Miró R; Navarro-Badal R; Jusmet-Miguel X; Calmarza P; Puzo-Foncilla JL; Alía-Ramos P; Candás-Estébanez B
PLoS One; 2018; 13(10):e0205430. PubMed ID: 30304062
[TBL] [Abstract][Full Text] [Related]
29. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
[TBL] [Abstract][Full Text] [Related]
30. Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia.
Climent E; Marco-Benedí V; Benaiges D; Pintó X; Suárez-Tembra M; Plana N; Lafuente H; Ortega-Martínez de Victoria E; Brea-Hernando Á; Vila À; Civeira F; Pedro-Botet J
Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1594-1603. PubMed ID: 33744038
[TBL] [Abstract][Full Text] [Related]
31. Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients.
Averna M; Zaninelli A; Le Grazie C; Gensini GF
J Clin Lipidol; 2010; 4(4):272-8. PubMed ID: 21122660
[TBL] [Abstract][Full Text] [Related]
32. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
33. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
34. Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study.
Chen Y; Li D; Jing J; Yan H; Liu J; Shen Z; James S; Varenhorst C
Clin Ther; 2017 Sep; 39(9):1827-1839.e1. PubMed ID: 28807393
[TBL] [Abstract][Full Text] [Related]
35. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
[TBL] [Abstract][Full Text] [Related]
36. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
[TBL] [Abstract][Full Text] [Related]
37. Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
Sebestjen M; Boh M; Keber I
Wien Klin Wochenschr; 2002 Dec; 114(23-24):999-1003. PubMed ID: 12635468
[TBL] [Abstract][Full Text] [Related]
38. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
[TBL] [Abstract][Full Text] [Related]
39. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis.
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
Eur J Prev Cardiol; 2016 May; 23(7):744-7. PubMed ID: 26246463
[TBL] [Abstract][Full Text] [Related]
40. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
